ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt
Release Date: 01/05/2010

Grantor: CDER IND/IDE Number: 49,484 Serial Number: 0212

A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation (ATHENA)

This study has been completed.

Sponsor:	Sanofi
Collaborators:	
Information provided by:	Sanofi
ClinicalTrials.gov Identifier:	NCT00174785

Purpose

To assess the efficacy of dronedarone in preventing cardiovascular hospitalization or death from any cause in a population of high-risk patients with atrial fibrillation/atrial flutter (AF/AFL).

To assess that dronedarone is well tolerated in this population.

Condition	Intervention	Phase
Atrial Fibrillation Atrial Flutter	Drug: dronedarone (SR33589) Drug: placebo	Phase 3

Study Type: Interventional
Study Design: Prevention, Parallel Assignment, Double Blind (Subject, Investigator), Randomized, Efficacy Study
Official Title: A Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL)

Further study details as provided by Sanofi:

Primary Outcome Measure:

- First Hospitalization for Cardiovascular Reason or Death From Any Cause [Time Frame: minimum follow-up duration: 1 year ; maximum: 2.5 years] [Designated as safety issue: No]

The primary event is the first hospitalization for cardiovascular reason or death from any cause, whichever is earlier, as assessed by the investigator. The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

Secondary Outcome Measures:

- Death From Any Cause [Time Frame: minimum follow-up duration: 1 year ; maximum: 2.5 years] [Designated as safety issue: No]
  The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
- First Hospitalization for Cardiovascular Reason [Time Frame: minimum follow-up duration: 1 year ; maximum: 2.5 years] [Designated as safety issue: No]
  The considered event is the first hospitalization for cardiovascular reason, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
- Cardiovascular Death [Time Frame: minimum follow-up duration: 1 year ; maximum: 2.5 years] [Designated as safety issue: No]
  The considered event is cardiovascular death, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

Other Pre-specified Outcome Measures:

- Adjudicated Cardiovascular Death [Time Frame: minimum follow-up duration: 1 year ; maximum: 2.5 years] [Designated as safety issue: No]
  The considered event is cardiovascular death, as assessed by the blinded adjudication of the Steering Committee. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.

Enrollment: 4628
Study Start Date: June 2005
Primary Completion Date: March 2008
Study Completion Date: March 2008

Arms	Assigned Interventions
Experimental: Dronedarone 400mg bid Dronedarone 400mg tablets twice daily (bid)	Drug: dronedarone (SR33589) oral administration (tablets) Other Names: Multaq®
Placebo Comparator: Placebo matching placebo tablets	Drug: placebo oral administration (tablets)

Detailed Description:

This is a prospective, multinational, double-blind, randomized, multi-center, placebo-controlled, parallel-group trial evaluating the effects of dronedarone versus placebo (ratio 1:1) over a minimum treatment duration of 12 months and a mean follow-up duration of 1.75 years (in AF/AFL patients). Patients can be included in the study while in atrial fibrillation/flutter or in sinus rhythm if conversion has occurred either spontaneously or following a procedure such as electrical cardioversion (or overdrive pacing) or administration of an antiarrhythmic drug.After randomization all patients will be followed until the common study end date; the last patient included in the study will be followed for 1 year. Visits will be at baseline, after 7 days, after 14 days, after one month, after three months and then every three months until end of the study. At each visit patients will be asked for the occurrence of hospitalizations or other events since the last visit. The study will be monitored by an independent Data Monitoring Committee (DMC) for safety, tolerability and efficacy.

Eligibility

Ages Eligible for Study: 70 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

- 1. Patients aged 75 years or older (70 years before protocol amendment 1), or patients aged at least 70 years (any age before protocol amendment 1) with one or more of the following risk factors at baseline:
    - Hypertension (taking antihypertensive drugs of at least two different classes)
    - Diabetes
    - Prior cerebrovascular accident (stroke or transient ischemic attack) or systemic embolism
    - Left atrium diameter greater than or equal to 50 mm by echocardiography
    - Left ventricular ejection fraction less than 0.40 by 2D-echocardiography (two-dimensional echocardiography)
- 2. Availability of one electrocardiogram (ECG) within the last 6 months, showing that the patient was or is in AF/AFL
- 3. Availability of one ECG within the last 6 months, showing that the patient was or is in sinus rhythm

Exclusion Criteria:

General criteria:

- 1. Refusal or inability to give informed consent to participate in the study
- 2. Any non cardiovascular illness or disorder that could preclude participation or severely limit survival including cancer with metastasis and organ transplantation requiring immune suppression
- 3. Pregnant women (pregnancy test must be negative) or women of childbearing potential not on adequate birth control: only women with a highly effective method of contraception [oral contraception or intra-uterine device (IUD)] or sterile can be randomized.
- 4. Breastfeeding women
- 5. Previous (2 preceding months) or current participation in another clinical trial with an investigational drug (under development) or with an investigational device
- 6. Previous participation in this trial

Criteria Related to a cardiac condition:

- 7. Patients in permanent atrial fibrillation
- 8. Patients in unstable hemodynamic condition such as acute pulmonary edema within 12 hours prior to start of study medication; cardiogenic shock; treatment with intra-venous pressor agents; patients on respirator; congestive heart failure of stage NYHA IV (New York Heart Association classification) within the last 4 weeks; uncorrected, hemodynamically significant primary obstructive valvular disease; hemodynamically significant obstructive cardiomyopathy; a cardiac operation or revascularization procedure within 4 weeks preceding randomization
- 9. Planned major non-cardiac or cardiac surgery or procedures including surgery for valvular heart disease, coronary artery bypass graft (CABG) , percutaneous coronary intervention (PCI) , or on urgent cardiac transplantation list
- 10. Acute myocarditis or constrictive pericarditis
- 11. Bradycardia < 50 bpm and/or PR-interval > 0.28 sec on the last 12-lead ECG
- 12. Significant sinus node disease (documented pause of 3 seconds or more) or 2nd or 3rd degree atrioventricular block (AV-block) unless treated with a pacemaker

Criteria Related to Concomitant Medications:

- 13. Need of a concomitant medication that is prohibited in this trial, including the requirement for Vaughan Williams Class I and III anti-arrhythmic drugs, that would preclude the use of study drug during the planned study period

Criteria Related to Laboratory Abnormalities:

- 14. Plasma potassium < 3.5 mmol/l (as anti-arrhythmic drugs can be arrhythmogenic in patients with hypokalemia, this must be corrected prior to randomization)
- 15. A calculated Glomerular Filtration Rate (GFR) at baseline <10 ml/min using the Cockroft Gault formula

Contacts and Locations

Locations

United States, New Jersey
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, United States, 08807
Argentina
Sanofi-Aventis Administrative Office
Buenos Aires, Argentina
Australia
Sanofi-Aventis Administrative Office
New South Wales, Australia
Austria
Sanofi-Aventis Administrative Office
Wien, Austria
Belgium
Sanofi-Aventis Administrative Office
Diegem, Belgium
Canada
Sanofi-Aventis Administrative Office
Laval, Canada
Chile
Sanofi-Aventis Administrative Office
Santiago, Chile
China
Sanofi-Aventis Administrative Office
Shangaï, China
Czech Republic
Sanofi-Aventis Administrative Office
Praha, Czech Republic
Finland
Sanofi-Aventis Administrative Office
Helsinki, Finland
Germany

Sanofi-aventis Administrative Office
Berlin, Germany
Greece
Sanofi-Aventis Administrative Office
Athens, Greece
Hong Kong
Sanofi-Aventis Administrative Office
Causeway Bay, Hong Kong
Hungary
Sanofi-Aventis Administrative Office
Budapest, Hungary
India
Sanofi-Aventis Administrative Office
Mumbai, India
Israel
Sanofi-Aventis Administrative Office
Natanya, Israel
Italy
Sanofi-Aventis Administrative Office
Milano, Italy
Korea, Republic of
Sanofi-Aventis Administrative Office
Seoul, Korea, Republic of
Malaysia
Sanofi-Aventis Administrative Office
Kuala Lumpur, Malaysia
Mexico
Sanofi-Aventis Administrative Office
Mexico, Mexico
Morocco
Sanofi-Aventis Administrative Office
Casablanca, Morocco
Netherlands
Sanofi-Aventis Administrative Office
Gouda, Netherlands
New Zealand
Sanofi-Aventis Administrative Office
Macquarie Park, New Zealand
Norway
Sanofi-Aventis Administrative Office
Lysaker, Norway
Philippines
Sanofi-Aventis Administrative Office
Makati City, Philippines
Poland

Sanofi-Aventis Administrative Office
Warszawa, Poland
Portugal
Sanofi-Aventis Administrative Office
Porto Salvo, Portugal
Russian Federation
Sanofi-Aventis Administrative Office
Moscow, Russian Federation
Singapore
Sanofi-Aventis Administrative Office
Singapore, Singapore
South Africa
Sanofi-Aventis Administrative Office
Midrand, South Africa
Spain
Sanofi-Aventis Administrative Office
Barcelona, Spain
Sweden
Sanofi-Aventis Administrative Office
Bromma, Sweden
Taiwan
Sanofi-Aventis Administrative Office
Taipei, Taiwan
Thailand
Sanofi-Aventis Administrative Office
Bangkok, Thailand
Tunisia
Sanofi-Aventis Administrative Office
Megrine, Tunisia
Turkey
Sanofi-Aventis Administrative Office
Istanbul, Turkey
United Kingdom
Sanofi-Aventis Administrative Office
Guildford Surrey, United Kingdom

Investigators

Study Director:	International Clinical Development	sanofi-aventis

More Information

http://www.sanofi-aventis.com

Results Publications:

Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009 Feb 12;360(7):668-78. doi: 10.1056/NEJMoa0803778. Erratum in: N Engl J Med. 2009 Jun 4;360(23):2487. N Engl J Med. 2011 Apr 14;364(15):1481.

Other Publications:

Hohnloser SH, Connolly SJ, Crijns HJ, Page RL, Seiz W, Torp-Petersen C. Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol. 2008 Jan;19(1):69-73. Epub 2007 Nov 21.

Responsible Party:	sanofi-aventis (International Clinical Development - Study Director)
Study ID Numbers:	EFC5555
Health Authority:	United States: Food and Drug Administration Netherlands: Medicines Evaluation Board (MEB) France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study Results

Participant Flow

Recruitment Details	Enrollment of patients started on June 29, 2005 and was completed on December 30, 2006. The study was conducted at 551 centers in 37 countries. The common study end date ensuring a minimum planned follow-up of one year was December 30th, 2007.

Reporting Groups

	Description
Dronedarone 400mg Bid	dronedarone tablets 400mg twice daily
Placebo	matching placebo tablets

Overall Study

	Dronedarone 400mg Bid	Placebo
Started	2301 [1]	2327 [2]
Completed	1605 [3]	1611 [3]
Not Completed	696	716
Adverse Event	293	191
Protocol Violation	14	14

	Dronedarone 400mg Bid	Placebo
Withdrawal by Subject	173	175
Atrial Fibrillation/Flutter recurrence	110	167
Prohibited antiarrhythmic medication	39	88
Other prohibited medication	5	3
Family request	6	8
Not pre-specified/Not coded	56	70

[1] randomized patients; among them, 10 patients did not receive any study drug in the dronedarone group
[2] randomized patients; among them, 14 patients did not receive any study drug in the placebo group
[3] completed study drug

Baseline Characteristics

Reporting Groups

	Description
Dronedarone 400mg Bid	dronedarone tablets 400mg twice daily
Placebo	matching placebo tablets

Baseline Measures

	Dronedarone 400mg Bid	Placebo	Total
Number of Participants	2301	2327	4628
Age, Customized [units: participants]			
18 to < 65 years	431	442	873
65 to < 75 years	923	907	1830
>= 75 years	947	978	1925
Age, Continuous [units: years] Mean (Standard Deviation)	71.6 (8.9)	71.7 (9.0)	71.6 (9.0)
Gender, Male/Female [units: participants]			
Female	1131	1038	2169

	Dronedarone 400mg Bid	Placebo	Total
Male	1170	1289	2459

Outcome Measures

1. Primary Outcome Measure:

Measure Title	First Hospitalization for Cardiovascular Reason or Death From Any Cause
Measure Description	The primary event is the first hospitalization for cardiovascular reason or death from any cause, whichever is earlier, as assessed by the investigator. The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
Time Frame	minimum follow-up duration: 1 year ; maximum: 2.5 years
Safety Issue?	No

Analysis Population Description

All efficacy analyses were performed on the "all randomized patients" population including all patients randomized irrespective of whether the patient actually received any drug or complied with the study protocol.

Reporting Groups

	Description
Dronedarone 400mg Bid	dronedarone tablets 400mg twice daily
Placebo	matching placebo tablets

Measured Values

	Dronedarone 400mg Bid	Placebo
Number of Participants Analyzed	2301	2327
First Hospitalization for Cardiovascular Reason or Death From Any Cause [units: participants]	734	917

Statistical Analysis 1 for First Hospitalization for Cardiovascular Reason or Death From Any Cause

Statistical Analysis Overview	Comparison Groups	Dronedarone 400mg Bid, Placebo
	Comments	[Not specified]
	Non-Inferiority or Equivalence Analysis?	No

	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.0001
	Comments	Cumulative incidence functions in each treatment group were calculated using non-parametric Kaplan-Meier estimates. Median time-to-event was not reached in any group. The primary comparison was performed at the 5% level using a 2-sided Log rank test.
	Method	Log Rank
	Comments	[Not specified]

Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.76
	Confidence Interval	(2-Sided) 95% 0.69 to 0.84
	Estimation Comments	The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It represents the relative hazard of first hospitalization for cardiovascular reason or death for the dronedarone group compared with the placebo group.

2. Secondary Outcome Measure:

Measure Title	Death From Any Cause
Measure Description	The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
Time Frame	minimum follow-up duration: 1 year ; maximum: 2.5 years
Safety Issue?	No

Analysis Population Description

"All randomized patients" population

Reporting Groups

	Description
Dronedarone 400mg Bid	dronedarone tablets 400mg twice daily
Placebo	matching placebo tablets

Measured Values

	Dronedarone 400mg Bid	Placebo
Number of Participants Analyzed	2301	2327

	Dronedarone 400mg Bid	Placebo
Death From Any Cause [units: participants]	116	139

Statistical Analysis 1 for Death From Any Cause

Statistical Analysis Overview	Comparison Groups	Dronedarone 400mg Bid, Placebo
	Comments	[Not specified]
	Non-Inferiority or Equivalence Analysis?	No
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.18
	Comments	Cumulative incidences calculated in each group using non-parametric Kaplan-Meier estimates. Median time-to-event was not reached in any group. Hierarchical procedure applied to secondary efficacy endpoints testing to protect the global type I error.
	Method	Log Rank
	Comments	[Not specified]

Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.84
	Confidence Interval	(2-Sided) 95% 0.66 to 1.08
	Estimation Comments	The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It represents the relative hazard of death from any cause for the dronedarone group compared with the placebo group.

3. Secondary Outcome Measure:

Measure Title	First Hospitalization for Cardiovascular Reason
Measure Description	The considered event is the first hospitalization for cardiovascular reason, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
Time Frame	minimum follow-up duration: 1 year ; maximum: 2.5 years
Safety Issue?	No

Analysis Population Description
"All randomized patients" population

Reporting Groups

	Description
Dronedarone 400mg Bid	dronedarone tablets 400mg twice daily
Placebo	matching placebo tablets

Measured Values

	Dronedarone 400mg Bid	Placebo
Number of Participants Analyzed	2301	2327
First Hospitalization for Cardiovascular Reason [units: participants]	675	859

Statistical Analysis 1 for First Hospitalization for Cardiovascular Reason

Statistical Analysis Overview	Comparison Groups	Dronedarone 400mg Bid, Placebo
	Comments	[Not specified]
	Non-Inferiority or Equivalence Analysis?	No
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.0001
	Comments	Cumulative incidences calculated in each group using non-parametric Kaplan-Meier estimates. Median time-to-event was not reached in any group. Hierarchical procedure applied to secondary efficacy endpoints testing to protect the global type I error.
	Method	Log Rank
	Comments	[Not specified]

Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.74
	Confidence Interval	(2-Sided) 95% 0.67 to 0.82

	Estimation Comments	The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It represents the relative hazard of first hospitalization for cardiovascular reason for the dronedarone group compared with the placebo group.

4. Secondary Outcome Measure:

Measure Title	Cardiovascular Death
Measure Description	The considered event is cardiovascular death, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
Time Frame	minimum follow-up duration: 1 year ; maximum: 2.5 years
Safety Issue?	No

Analysis Population Description

"All randomized patients" population

Reporting Groups

	Description
Dronedarone 400mg Bid	dronedarone tablets 400mg twice daily
Placebo	matching placebo tablets

Measured Values

	Dronedarone 400mg Bid	Placebo
Number of Participants Analyzed	2301	2327
Cardiovascular Death [units: participants]	65	94

Statistical Analysis 1 for Cardiovascular Death

Statistical Analysis Overview	Comparison Groups	Dronedarone 400mg Bid, Placebo
	Comments	[Not specified]
	Non-Inferiority or Equivalence Analysis?	No
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.025
	Comments	Cumulative incidences calculated in each group using non-parametric Kaplan-Meier estimates. Median time-to-event was not reached in any group. Hierarchical procedure applied to secondary efficacy endpoints testing to protect the global type I error.
	Method	Log Rank
	Comments	[Not specified]

Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.70
	Confidence Interval	(2-Sided) 95% 0.51 to 0.96
	Estimation Comments	The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It represents the relative hazard of cardiovascular death for the dronedarone group compared with the placebo group.

5. Other Pre-specified Outcome Measure:

Measure Title	Adjudicated Cardiovascular Death
Measure Description	The considered event is cardiovascular death, as assessed by the blinded adjudication of the Steering Committee. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
Time Frame	minimum follow-up duration: 1 year ; maximum: 2.5 years
Safety Issue?	No

Analysis Population Description

"All randomized patients" population

Reporting Groups

	Description
Dronedarone 400mg Bid	dronedarone tablets 400mg twice daily
Placebo	matching placebo tablets

Measured Values

	Dronedarone 400mg Bid	Placebo
Number of Participants Analyzed	2301	2327
Adjudicated Cardiovascular Death	63	90

	Dronedarone 400mg Bid	Placebo
[units: participants]		

Statistical Analysis 1 for Adjudicated Cardiovascular Death

Statistical Analysis Overview	Comparison Groups	Dronedarone 400mg Bid, Placebo
	Comments	[Not specified]
	Non-Inferiority or Equivalence Analysis?	No
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.03
	Comments	Cumulative incidences calculated in each group using non-parametric Kaplan-Meier estimates. Median time-to-event was not reached in any group. The comparison was performed at the 5% level using a 2-sided Log rank
	Method	Log Rank
	Comments	[Not specified]

Method of Estimation	Estimation Parameter	Hazard Ratio (HR)
	Estimated Value	0.71
	Confidence Interval	(2-Sided) 95% 0.51 to 0.98
	Estimation Comments	The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It represents the relative hazard of adjudicated cardiovascular death for the dronedarone group compared with the placebo group.

Reported Adverse Events

Time Frame	In both treatment groups, the median duration of exposure was about 18 months, with a maximum of 30 months.
Additional Description	Reported Events are Treatment-Emergent Adverse Events with an onset date between the first study drug intake and the last study drug intake + 10 days and any pre-treatment adverse event that led to study drug permanent discontinuation.

Reporting Groups

	Description
Dronedarone 400mg Bid	dronedarone tablets 400mg twice daily
Placebo	matching placebo tablets

Serious Adverse Events

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Total	456/2291 (19.9%)	489/2313 (21.14%)
Blood and lymphatic system disorders		
Anaemia [A] *	4/2291 (0.17%)	7/2313 (0.3%)
Anaemia haemolytic autoimmune [A] *	0/2291 (0%)	1/2313 (0.04%)
Anaemia macrocytic [A] *	1/2291 (0.04%)	0/2313 (0%)
Anaemia of chronic disease [A] *	0/2291 (0%)	1/2313 (0.04%)
Anaemia of malignant disease [A] *	1/2291 (0.04%)	0/2313 (0%)
Haemorrhagic anaemia [A] *	1/2291 (0.04%)	0/2313 (0%)
Hypochromic anaemia [A] *	0/2291 (0%)	2/2313 (0.09%)
Iron deficiency anaemia [A] *	0/2291 (0%)	4/2313 (0.17%)
Leukocytosis [A] *	1/2291 (0.04%)	0/2313 (0%)
Lymphadenitis [A] *	1/2291 (0.04%)	0/2313 (0%)
Pancytopenia [A] *	0/2291 (0%)	1/2313 (0.04%)
Splenic infarction [A] *	2/2291 (0.09%)	0/2313 (0%)
Spontaneous haematoma [A] *	1/2291 (0.04%)	0/2313 (0%)
Cardiac disorders		
Acute myocardial infarction [A] *	1/2291 (0.04%)	0/2313 (0%)
Angina pectoris [A] *	1/2291 (0.04%)	0/2313 (0%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Angina unstable [A] *	0/2291 (0%)	1/2313 (0.04%)
Aortic valve calcification [A] *	0/2291 (0%)	1/2313 (0.04%)
Aortic valve incompetence [A] *	0/2291 (0%)	1/2313 (0.04%)
Atrioventricular block complete [A] *	0/2291 (0%)	1/2313 (0.04%)
Bradycardia [A] *	2/2291 (0.09%)	3/2313 (0.13%)
Cardiac failure [A] *	2/2291 (0.09%)	2/2313 (0.09%)
Cardiac failure congestive [A] *	0/2291 (0%)	2/2313 (0.09%)
Cardiac perforation [A] *	0/2291 (0%)	1/2313 (0.04%)
Cardiac tamponade [A] *	1/2291 (0.04%)	0/2313 (0%)
Coronary artery disease [A] *	1/2291 (0.04%)	0/2313 (0%)
Pericardial effusion [A] *	2/2291 (0.09%)	1/2313 (0.04%)
Pericardial haemorrhage [A] *	1/2291 (0.04%)	0/2313 (0%)
Right ventricular failure [A] *	0/2291 (0%)	1/2313 (0.04%)
Sinus bradycardia [A] *	1/2291 (0.04%)	0/2313 (0%)
Torsade de pointes [A] *	1/2291 (0.04%)	0/2313 (0%)
Ventricle rupture [A] *	1/2291 (0.04%)	0/2313 (0%)
Ventricular extrasystoles [A] *	1/2291 (0.04%)	0/2313 (0%)
Ventricular flutter [A] *	0/2291 (0%)	1/2313 (0.04%)
Ventricular tachycardia [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Congenital, familial and genetic disorders		
Hydrocele [A] *	0/2291 (0%)	1/2313 (0.04%)
Ear and labyrinth disorders		

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Hearing impaired [A] *	0/2291 (0%)	1/2313 (0.04%)
Inner ear disorder [A] *	0/2291 (0%)	1/2313 (0.04%)
Vertigo [A] *	2/2291 (0.09%)	4/2313 (0.17%)
Vertigo positional [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Vestibular neuronitis [A] *	0/2291 (0%)	1/2313 (0.04%)
Endocrine disorders		
Adrenal disorder [A] *	0/2291 (0%)	1/2313 (0.04%)
Basedow's disease [A] *	0/2291 (0%)	2/2313 (0.09%)
Goitre [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Hyperthyroidism [A] *	2/2291 (0.09%)	0/2313 (0%)
Hypothyroidism [A] *	1/2291 (0.04%)	0/2313 (0%)
Inappropriate antidiuretic hormone secretion [A] *	0/2291 (0%)	1/2313 (0.04%)
Eye disorders		
Blindness [A] *	0/2291 (0%)	1/2313 (0.04%)
Cataract [A] *	4/2291 (0.17%)	3/2313 (0.13%)
Endophthalmitis [A] *	0/2291 (0%)	1/2313 (0.04%)
Glaucoma [A] *	3/2291 (0.13%)	1/2313 (0.04%)
Maculopathy [A] *	1/2291 (0.04%)	0/2313 (0%)
Myopia [A] *	0/2291 (0%)	1/2313 (0.04%)
Ocular retrobulbar haemorrhage [A] *	0/2291 (0%)	1/2313 (0.04%)
Open angle glaucoma [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Optic ischaemic neuropathy [A] *	0/2291 (0%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Pterygium [A] *	0/2291 (0%)	1/2313 (0.04%)
Retinal detachment [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Ulcerative keratitis [A] *	1/2291 (0.04%)	0/2313 (0%)
Uveitis [A] *	0/2291 (0%)	1/2313 (0.04%)
Gastrointestinal disorders		
Abdominal adhesions [A] *	2/2291 (0.09%)	0/2313 (0%)
Abdominal hernia [A] *	2/2291 (0.09%)	0/2313 (0%)
Abdominal pain [A] *	4/2291 (0.17%)	2/2313 (0.09%)
Abdominal pain upper [A] *	2/2291 (0.09%)	2/2313 (0.09%)
Abdominal strangulated hernia [A] *	2/2291 (0.09%)	0/2313 (0%)
Anal prolapse [A] *	1/2291 (0.04%)	0/2313 (0%)
Appendicitis perforated [A] *	0/2291 (0%)	2/2313 (0.09%)
Colitis [A] *	1/2291 (0.04%)	2/2313 (0.09%)
Colitis ischaemic [A] *	1/2291 (0.04%)	2/2313 (0.09%)
Colitis ulcerative [A] *	0/2291 (0%)	1/2313 (0.04%)
Colonic polyp [A] *	3/2291 (0.13%)	1/2313 (0.04%)
Constipation [A] *	2/2291 (0.09%)	0/2313 (0%)
Crohn's disease [A] *	2/2291 (0.09%)	0/2313 (0%)
Diarrhoea [A] *	6/2291 (0.26%)	4/2313 (0.17%)
Diverticular perforation [A] *	0/2291 (0%)	1/2313 (0.04%)
Diverticulum [A] *	0/2291 (0%)	2/2313 (0.09%)
Diverticulum intestinal [A] *	0/2291 (0%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Diverticulum intestinal haemorrhagic [A] *	1/2291 (0.04%)	0/2313 (0%)
Duodenal ulcer [A] *	1/2291 (0.04%)	0/2313 (0%)
Duodenal ulcer haemorrhage [A] *	0/2291 (0%)	1/2313 (0.04%)
Dyspepsia [A] *	1/2291 (0.04%)	0/2313 (0%)
Dysphagia [A] *	0/2291 (0%)	2/2313 (0.09%)
Femoral hernia, obstructive [A] *	1/2291 (0.04%)	0/2313 (0%)
Food poisoning [A] *	1/2291 (0.04%)	0/2313 (0%)
Gastric haemorrhage [A] *	2/2291 (0.09%)	0/2313 (0%)
Gastric polyps [A] *	0/2291 (0%)	1/2313 (0.04%)
Gastric ulcer [A] *	1/2291 (0.04%)	3/2313 (0.13%)
Gastric ulcer haemorrhage [A] *	0/2291 (0%)	2/2313 (0.09%)
Gastritis [A] *	5/2291 (0.22%)	4/2313 (0.17%)
Gastritis erosive [A] *	1/2291 (0.04%)	0/2313 (0%)
Gastritis haemorrhagic [A] *	1/2291 (0.04%)	0/2313 (0%)
Gastroduodenitis [A] *	1/2291 (0.04%)	0/2313 (0%)
Gastrointestinal haemorrhage [A] *	6/2291 (0.26%)	5/2313 (0.22%)
Gastrooesophageal reflux disease [A] *	2/2291 (0.09%)	3/2313 (0.13%)
Haematemesis [A] *	0/2291 (0%)	1/2313 (0.04%)
Haematochezia [A] *	0/2291 (0%)	1/2313 (0.04%)
Haemorrhoidal haemorrhage [A] *	2/2291 (0.09%)	0/2313 (0%)
Haemorrhoids [A] *	0/2291 (0%)	1/2313 (0.04%)
Hiatus hernia, obstructive [A] *	0/2291 (0%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Ileus [A] *	2/2291 (0.09%)	0/2313 (0%)
Ileus paralytic [A] *	1/2291 (0.04%)	0/2313 (0%)
Infrequent bowel movements [A] *	1/2291 (0.04%)	0/2313 (0%)
Inguinal hernia [A] *	3/2291 (0.13%)	3/2313 (0.13%)
Intestinal fistula [A] *	1/2291 (0.04%)	0/2313 (0%)
Intestinal haemorrhage [A] *	0/2291 (0%)	1/2313 (0.04%)
Intestinal obstruction [A] *	1/2291 (0.04%)	3/2313 (0.13%)
Intussusception [A] *	0/2291 (0%)	1/2313 (0.04%)
Irritable bowel syndrome [A] *	0/2291 (0%)	1/2313 (0.04%)
Lower gastrointestinal haemorrhage [A] *	0/2291 (0%)	2/2313 (0.09%)
Lumbar hernia [A] *	1/2291 (0.04%)	0/2313 (0%)
Mallory-weiss syndrome [A] *	2/2291 (0.09%)	0/2313 (0%)
Mesenteric artery thrombosis [A] *	0/2291 (0%)	1/2313 (0.04%)
Mesenteric occlusion [A] *	0/2291 (0%)	1/2313 (0.04%)
Mouth haemorrhage [A] *	1/2291 (0.04%)	0/2313 (0%)
Nausea [A] *	2/2291 (0.09%)	2/2313 (0.09%)
Oedematous pancreatitis [A] *	0/2291 (0%)	1/2313 (0.04%)
Oesophageal mass [A] *	1/2291 (0.04%)	0/2313 (0%)
Oesophageal spasm [A] *	1/2291 (0.04%)	0/2313 (0%)
Oesophagitis [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Oesophagitis ulcerative [A] *	1/2291 (0.04%)	0/2313 (0%)
Pancreatitis [A] *	3/2291 (0.13%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Pancreatitis acute [A] *	4/2291 (0.17%)	3/2313 (0.13%)
Peptic ulcer haemorrhage [A] *	0/2291 (0%)	1/2313 (0.04%)
Peritonitis [A] *	1/2291 (0.04%)	0/2313 (0%)
Rectal haemorrhage [A] *	1/2291 (0.04%)	3/2313 (0.13%)
Reflux oesophagitis [A] *	1/2291 (0.04%)	0/2313 (0%)
Short-bowel syndrome [A] *	0/2291 (0%)	1/2313 (0.04%)
Small intestinal obstruction [A] *	4/2291 (0.17%)	1/2313 (0.04%)
Thrombosis mesenteric vessel [A] *	1/2291 (0.04%)	2/2313 (0.09%)
Toothache [A] *	1/2291 (0.04%)	0/2313 (0%)
Umbilical hernia [A] *	0/2291 (0%)	1/2313 (0.04%)
Upper gastrointestinal haemorrhage [A] *	1/2291 (0.04%)	0/2313 (0%)
Vomiting [A] *	2/2291 (0.09%)	0/2313 (0%)
General disorders		
Asthenia [A] *	3/2291 (0.13%)	3/2313 (0.13%)
Drowning [A] *	1/2291 (0.04%)	0/2313 (0%)
General physical health deterioration [A] *	1/2291 (0.04%)	2/2313 (0.09%)
Hernia [A] *	0/2291 (0%)	1/2313 (0.04%)
Impaired healing [A] *	0/2291 (0%)	1/2313 (0.04%)
Implant site haematoma [A] *	0/2291 (0%)	1/2313 (0.04%)
Injection site haematoma [A] *	0/2291 (0%)	1/2313 (0.04%)
Multi-organ failure [A] *	0/2291 (0%)	2/2313 (0.09%)
Non-cardiac chest pain [A] *	4/2291 (0.17%)	3/2313 (0.13%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Oedema [A] *	1/2291 (0.04%)	0/2313 (0%)
Oedema peripheral [A] *	1/2291 (0.04%)	0/2313 (0%)
Pyrexia [A] *	2/2291 (0.09%)	2/2313 (0.09%)
Hepatobiliary disorders		
Bile duct stone [A] *	2/2291 (0.09%)	1/2313 (0.04%)
Biliary colic [A] *	2/2291 (0.09%)	0/2313 (0%)
Cholangitis [A] *	4/2291 (0.17%)	0/2313 (0%)
Cholecystitis [A] *	6/2291 (0.26%)	4/2313 (0.17%)
Cholecystitis acute [A] *	6/2291 (0.26%)	5/2313 (0.22%)
Cholecystitis chronic [A] *	1/2291 (0.04%)	2/2313 (0.09%)
Cholelithiasis [A] *	3/2291 (0.13%)	7/2313 (0.3%)
Cholestasis [A] *	0/2291 (0%)	1/2313 (0.04%)
Cytolytic hepatitis [A] *	0/2291 (0%)	1/2313 (0.04%)
Hepatic cirrhosis [A] *	0/2291 (0%)	2/2313 (0.09%)
Hepatitis toxic [A] *	1/2291 (0.04%)	0/2313 (0%)
Jaundice [A] *	1/2291 (0.04%)	0/2313 (0%)
Immune system disorders		
Hypersensitivity [A] *	1/2291 (0.04%)	0/2313 (0%)
Sarcoidosis [A] *	0/2291 (0%)	1/2313 (0.04%)
Infections and infestations		
Abdominal abscess [A] *	0/2291 (0%)	1/2313 (0.04%)
Abscess [A] *	1/2291 (0.04%)	0/2313 (0%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Abscess limb [A] *	1/2291 (0.04%)	0/2313 (0%)
Abscess oral [A] *	1/2291 (0.04%)	0/2313 (0%)
Acarodermatitis [A] *	1/2291 (0.04%)	0/2313 (0%)
Appendicitis [A] *	4/2291 (0.17%)	2/2313 (0.09%)
Bacteraemia [A] *	0/2291 (0%)	1/2313 (0.04%)
Bronchiectasis [A] *	2/2291 (0.09%)	0/2313 (0%)
Bronchitis [A] *	4/2291 (0.17%)	3/2313 (0.13%)
Bronchopneumonia [A] *	4/2291 (0.17%)	2/2313 (0.09%)
Bursitis infective [A] *	0/2291 (0%)	1/2313 (0.04%)
Cellulitis [A] *	5/2291 (0.22%)	7/2313 (0.3%)
Clonorchiasis [A] *	1/2291 (0.04%)	0/2313 (0%)
Clostridium difficile colitis [A] *	0/2291 (0%)	2/2313 (0.09%)
Device related infection [A] *	0/2291 (0%)	3/2313 (0.13%)
Diabetic gangrene [A] *	0/2291 (0%)	1/2313 (0.04%)
Diarrhoea infectious [A] *	1/2291 (0.04%)	0/2313 (0%)
Diverticulitis [A] *	4/2291 (0.17%)	4/2313 (0.17%)
Encephalitis viral [A] *	1/2291 (0.04%)	0/2313 (0%)
Epstein-barr virus infection [A] *	1/2291 (0.04%)	0/2313 (0%)
Erysipelas [A] *	0/2291 (0%)	4/2313 (0.17%)
Escherichia sepsis [A] *	1/2291 (0.04%)	0/2313 (0%)
Gastroenteritis [A] *	5/2291 (0.22%)	6/2313 (0.26%)
Gastroenteritis salmonella [A] *	0/2291 (0%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Gastroenteritis viral [A] *	1/2291 (0.04%)	0/2313 (0%)
Groin infection [A] *	0/2291 (0%)	1/2313 (0.04%)
Hepatitis a [A] *	1/2291 (0.04%)	0/2313 (0%)
Herpes zoster [A] *	2/2291 (0.09%)	1/2313 (0.04%)
Hiv infection [A] *	0/2291 (0%)	1/2313 (0.04%)
Infected epidermal cyst [A] *	1/2291 (0.04%)	0/2313 (0%)
Infection [A] *	1/2291 (0.04%)	0/2313 (0%)
Infective exacerbation of chronic obstructive airways disease [A] *	0/2291 (0%)	1/2313 (0.04%)
Influenza [A] *	1/2291 (0.04%)	0/2313 (0%)
Labyrinthitis [A] *	0/2291 (0%)	1/2313 (0.04%)
Lobar pneumonia [A] *	5/2291 (0.22%)	6/2313 (0.26%)
Localised infection [A] *	1/2291 (0.04%)	0/2313 (0%)
Lower respiratory tract infection [A] *	0/2291 (0%)	1/2313 (0.04%)
Mastitis [A] *	2/2291 (0.09%)	0/2313 (0%)
Obstructive chronic bronchitis with acute exacerbation [A] *	0/2291 (0%)	2/2313 (0.09%)
Opisthorchiasis [A] *	1/2291 (0.04%)	0/2313 (0%)
Orchitis [A] *	1/2291 (0.04%)	0/2313 (0%)
Osteomyelitis [A] *	1/2291 (0.04%)	0/2313 (0%)
Osteomyelitis chronic [A] *	1/2291 (0.04%)	0/2313 (0%)
Pancreatitis viral [A] *	1/2291 (0.04%)	0/2313 (0%)
Paronychia [A] *	0/2291 (0%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Peridiverticular abscess [A] *	0/2291 (0%)	1/2313 (0.04%)
Peritoneal infection [A] *	1/2291 (0.04%)	0/2313 (0%)
Peritonsillar abscess [A] *	0/2291 (0%)	1/2313 (0.04%)
Pneumonia [A] *	32/2291 (1.4%)	45/2313 (1.95%)
Pneumonia bacterial [A] *	1/2291 (0.04%)	0/2313 (0%)
Pneumonia klebsiella [A] *	1/2291 (0.04%)	0/2313 (0%)
Pneumonia legionella [A] *	0/2291 (0%)	1/2313 (0.04%)
Pneumonia pneumococcal [A] *	0/2291 (0%)	1/2313 (0.04%)
Pneumonia staphylococcal [A] *	0/2291 (0%)	1/2313 (0.04%)
Post procedural infection [A] *	0/2291 (0%)	1/2313 (0.04%)
Postoperative wound infection [A] *	0/2291 (0%)	2/2313 (0.09%)
Pyelonephritis [A] *	2/2291 (0.09%)	1/2313 (0.04%)
Pyelonephritis acute [A] *	0/2291 (0%)	2/2313 (0.09%)
Pyelonephritis chronic [A] *	2/2291 (0.09%)	2/2313 (0.09%)
Pyothorax [A] *	0/2291 (0%)	1/2313 (0.04%)
Rectal abscess [A] *	1/2291 (0.04%)	0/2313 (0%)
Respiratory tract infection [A] *	1/2291 (0.04%)	0/2313 (0%)
Respiratory tract infection viral [A] *	2/2291 (0.09%)	0/2313 (0%)
Sepsis [A] *	3/2291 (0.13%)	3/2313 (0.13%)
Septic shock [A] *	1/2291 (0.04%)	4/2313 (0.17%)
Sinusitis [A] *	0/2291 (0%)	3/2313 (0.13%)
Skin infection [A] *	1/2291 (0.04%)	0/2313 (0%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Soft tissue infection [A] *	1/2291 (0.04%)	0/2313 (0%)
Staphylococcal infection [A] *	0/2291 (0%)	1/2313 (0.04%)
Staphylococcal sepsis [A] *	0/2291 (0%)	1/2313 (0.04%)
Tinea cruris [A] *	0/2291 (0%)	1/2313 (0.04%)
Tracheobronchitis [A] *	0/2291 (0%)	1/2313 (0.04%)
Upper respiratory tract infection [A] *	1/2291 (0.04%)	3/2313 (0.13%)
Urinary tract infection [A] *	6/2291 (0.26%)	10/2313 (0.43%)
Urosepsis [A] *	2/2291 (0.09%)	4/2313 (0.17%)
Viral infection [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Wound infection bacterial [A] *	1/2291 (0.04%)	0/2313 (0%)
Injury, poisoning and procedural complications		
Accidental overdose [A] *	2/2291 (0.09%)	1/2313 (0.04%)
Acetabulum fracture [A] *	1/2291 (0.04%)	0/2313 (0%)
Alcohol poisoning [A] *	2/2291 (0.09%)	0/2313 (0%)
Anaemia postoperative [A] *	1/2291 (0.04%)	0/2313 (0%)
Anastomotic complication [A] *	1/2291 (0.04%)	0/2313 (0%)
Ankle fracture [A] *	0/2291 (0%)	3/2313 (0.13%)
Arterial injury [A] *	0/2291 (0%)	1/2313 (0.04%)
Asbestosis [A] *	1/2291 (0.04%)	0/2313 (0%)
Brain contusion [A] *	1/2291 (0.04%)	2/2313 (0.09%)
Cervical vertebral fracture [A] *	1/2291 (0.04%)	0/2313 (0%)
Concussion [A] *	0/2291 (0%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Contusion [A] *	3/2291 (0.13%)	2/2313 (0.09%)
Device failure [A] *	1/2291 (0.04%)	0/2313 (0%)
Device migration [A] *	0/2291 (0%)	1/2313 (0.04%)
Dislocation of joint prosthesis [A] *	0/2291 (0%)	5/2313 (0.22%)
Facial bones fracture [A] *	0/2291 (0%)	1/2313 (0.04%)
Fall [A] *	20/2291 (0.87%)	20/2313 (0.86%)
Femoral neck fracture [A] *	3/2291 (0.13%)	0/2313 (0%)
Femur fracture [A] *	2/2291 (0.09%)	1/2313 (0.04%)
Fibula fracture [A] *	0/2291 (0%)	1/2313 (0.04%)
Foot fracture [A] *	1/2291 (0.04%)	0/2313 (0%)
Graft thrombosis [A] *	0/2291 (0%)	1/2313 (0.04%)
Hand fracture [A] *	0/2291 (0%)	1/2313 (0.04%)
Head injury [A] *	1/2291 (0.04%)	0/2313 (0%)
Hip fracture [A] *	5/2291 (0.22%)	2/2313 (0.09%)
Humerus fracture [A] *	1/2291 (0.04%)	3/2313 (0.13%)
Incisional hernia [A] *	1/2291 (0.04%)	0/2313 (0%)
Injury [A] *	0/2291 (0%)	1/2313 (0.04%)
Joint dislocation [A] *	0/2291 (0%)	1/2313 (0.04%)
Joint injury [A] *	1/2291 (0.04%)	0/2313 (0%)
Lower limb fracture [A] *	2/2291 (0.09%)	0/2313 (0%)
Lumbar vertebral fracture [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Medical device pain [A] *	1/2291 (0.04%)	0/2313 (0%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Muscle injury [A] *	0/2291 (0%)	1/2313 (0.04%)
Operative haemorrhage [A] *	0/2291 (0%)	1/2313 (0.04%)
Overdose [A] *	0/2291 (0%)	1/2313 (0.04%)
Patella fracture [A] *	1/2291 (0.04%)	0/2313 (0%)
Pelvic fracture [A] *	0/2291 (0%)	1/2313 (0.04%)
Penetrating abdominal trauma [A] *	0/2291 (0%)	1/2313 (0.04%)
Post procedural haematoma [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Post procedural haemorrhage [A] *	1/2291 (0.04%)	0/2313 (0%)
Post-traumatic pain [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Postoperative heterotopic calcification [A] *	1/2291 (0.04%)	0/2313 (0%)
Procedural pain [A] *	0/2291 (0%)	1/2313 (0.04%)
Pubic rami fracture [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Rib fracture [A] *	2/2291 (0.09%)	1/2313 (0.04%)
Road traffic accident [A] *	3/2291 (0.13%)	3/2313 (0.13%)
Skull fracture [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Spinal compression fracture [A] *	1/2291 (0.04%)	4/2313 (0.17%)
Spinal cord injury cervical [A] *	0/2291 (0%)	1/2313 (0.04%)
Subdural haematoma [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Tendon rupture [A] *	2/2291 (0.09%)	2/2313 (0.09%)
Therapeutic agent toxicity [A] *	3/2291 (0.13%)	0/2313 (0%)
Transfusion reaction [A] *	1/2291 (0.04%)	0/2313 (0%)
Traumatic arthritis [A] *	1/2291 (0.04%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Traumatic arthropathy [A] *	0/2291 (0%)	1/2313 (0.04%)
Traumatic haematoma [A] *	1/2291 (0.04%)	3/2313 (0.13%)
Investigations		
Alanine aminotransferase increased [A] *	0/2291 (0%)	1/2313 (0.04%)
Aspartate aminotransferase increased [A] *	0/2291 (0%)	1/2313 (0.04%)
Blood creatine phosphokinase increased [A] *	0/2291 (0%)	1/2313 (0.04%)
Blood creatinine increased [A] *	5/2291 (0.22%)	1/2313 (0.04%)
Cardioactive drug level increased [A] *	1/2291 (0.04%)	0/2313 (0%)
Coagulation test abnormal [A] *	1/2291 (0.04%)	0/2313 (0%)
Electrocardiogram qt prolonged [A] *	4/2291 (0.17%)	1/2313 (0.04%)
Glycosylated haemoglobin increased [A] *	0/2291 (0%)	1/2313 (0.04%)
Hepatitis c positive [A] *	0/2291 (0%)	1/2313 (0.04%)
International normalised ratio decreased [A] *	1/2291 (0.04%)	0/2313 (0%)
International normalised ratio increased [A] *	4/2291 (0.17%)	6/2313 (0.26%)
Prothrombin time prolonged [A] *	1/2291 (0.04%)	0/2313 (0%)
Transaminases increased [A] *	0/2291 (0%)	1/2313 (0.04%)
Weight decreased [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Metabolism and nutrition disorders		
Anorexia [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Dehydration [A] *	4/2291 (0.17%)	10/2313 (0.43%)
Diabetes mellitus [A] *	4/2291 (0.17%)	3/2313 (0.13%)
Failure to thrive [A] *	0/2291 (0%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Fluid overload [A] *	1/2291 (0.04%)	0/2313 (0%)
Gout [A] *	1/2291 (0.04%)	2/2313 (0.09%)
Hyperglycaemia [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Hyperkalaemia [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Hypoglycaemia [A] *	3/2291 (0.13%)	3/2313 (0.13%)
Hypokalaemia [A] *	2/2291 (0.09%)	3/2313 (0.13%)
Hyponatraemia [A] *	3/2291 (0.13%)	2/2313 (0.09%)
Metabolic acidosis [A] *	1/2291 (0.04%)	0/2313 (0%)
Type 2 diabetes mellitus [A] *	0/2291 (0%)	1/2313 (0.04%)
Vitamin b12 deficiency [A] *	1/2291 (0.04%)	0/2313 (0%)
Musculoskeletal and connective tissue disorders		
Arthralgia [A] *	4/2291 (0.17%)	2/2313 (0.09%)
Arthropathy [A] *	1/2291 (0.04%)	0/2313 (0%)
Back pain [A] *	1/2291 (0.04%)	5/2313 (0.22%)
Bursitis [A] *	1/2291 (0.04%)	0/2313 (0%)
Dupuytren's contracture [A] *	1/2291 (0.04%)	0/2313 (0%)
Gouty arthritis [A] *	1/2291 (0.04%)	0/2313 (0%)
Haemarthrosis [A] *	0/2291 (0%)	1/2313 (0.04%)
Intervertebral disc compression [A] *	0/2291 (0%)	1/2313 (0.04%)
Intervertebral disc protrusion [A] *	2/2291 (0.09%)	0/2313 (0%)
Joint swelling [A] *	1/2291 (0.04%)	0/2313 (0%)
Lumbar spinal stenosis [A] *	1/2291 (0.04%)	2/2313 (0.09%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Muscle spasms [A] *	1/2291 (0.04%)	0/2313 (0%)
Muscular weakness [A] *	1/2291 (0.04%)	4/2313 (0.17%)
Musculoskeletal chest pain [A] *	2/2291 (0.09%)	2/2313 (0.09%)
Neck mass [A] *	0/2291 (0%)	1/2313 (0.04%)
Osteoarthritis [A] *	15/2291 (0.65%)	21/2313 (0.91%)
Osteonecrosis [A] *	0/2291 (0%)	1/2313 (0.04%)
Osteoporotic fracture [A] *	0/2291 (0%)	1/2313 (0.04%)
Pain in extremity [A] *	1/2291 (0.04%)	3/2313 (0.13%)
Pathological fracture [A] *	0/2291 (0%)	1/2313 (0.04%)
Polyarthritis [A] *	0/2291 (0%)	1/2313 (0.04%)
Polymyalgia rheumatica [A] *	0/2291 (0%)	1/2313 (0.04%)
Rhabdomyolysis [A] *	0/2291 (0%)	1/2313 (0.04%)
Rheumatoid arthritis [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Rotator cuff syndrome [A] *	1/2291 (0.04%)	4/2313 (0.17%)
Spondylolisthesis acquired [A] *	1/2291 (0.04%)	0/2313 (0%)
Spondylolysis [A] *	0/2291 (0%)	1/2313 (0.04%)
Sympathetic posterior cervical syndrome [A] *	1/2291 (0.04%)	0/2313 (0%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Acute myeloid leukaemia [A] *	1/2291 (0.04%)	0/2313 (0%)
Adrenal adenoma [A] *	0/2291 (0%)	1/2313 (0.04%)
B-cell lymphoma [A] *	2/2291 (0.09%)	1/2313 (0.04%)
Basal cell carcinoma [A] *	2/2291 (0.09%)	3/2313 (0.13%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Benign neoplasm of thyroid gland [A] *	1/2291 (0.04%)	0/2313 (0%)
Benign peritoneal neoplasm [A] *	0/2291 (0%)	1/2313 (0.04%)
Bladder cancer [A] *	1/2291 (0.04%)	3/2313 (0.13%)
Bladder neoplasm [A] *	2/2291 (0.09%)	0/2313 (0%)
Bladder papilloma [A] *	1/2291 (0.04%)	0/2313 (0%)
Bladder transitional cell carcinoma [A] *	1/2291 (0.04%)	0/2313 (0%)
Brain neoplasm [A] *	1/2291 (0.04%)	0/2313 (0%)
Breast cancer [A] *	3/2291 (0.13%)	5/2313 (0.22%)
Breast cancer recurrent [A] *	0/2291 (0%)	1/2313 (0.04%)
Breast cancer stage iii [A] *	0/2291 (0%)	1/2313 (0.04%)
Bronchial carcinoma [A] *	0/2291 (0%)	1/2313 (0.04%)
Bronchioloalveolar carcinoma [A] *	1/2291 (0.04%)	0/2313 (0%)
Carcinoid tumour pulmonary [A] *	1/2291 (0.04%)	0/2313 (0%)
Colon adenoma [A] *	1/2291 (0.04%)	0/2313 (0%)
Colon cancer [A] *	5/2291 (0.22%)	5/2313 (0.22%)
Colorectal cancer [A] *	0/2291 (0%)	1/2313 (0.04%)
Endometrial cancer [A] *	1/2291 (0.04%)	0/2313 (0%)
Gastric cancer [A] *	0/2291 (0%)	1/2313 (0.04%)
Glioblastoma [A] *	0/2291 (0%)	1/2313 (0.04%)
Hepatic neoplasm [A] *	1/2291 (0.04%)	0/2313 (0%)
Hepatic neoplasm malignant [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Inflammatory carcinoma of the breast [A] *	0/2291 (0%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Large intestine carcinoma [A] *	0/2291 (0%)	1/2313 (0.04%)
Leiomyosarcoma metastatic [A] *	1/2291 (0.04%)	0/2313 (0%)
Lip and/or oral cavity cancer [A] *	0/2291 (0%)	1/2313 (0.04%)
Lung adenocarcinoma [A] *	1/2291 (0.04%)	2/2313 (0.09%)
Lung adenocarcinoma metastatic [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Lung cancer metastatic [A] *	1/2291 (0.04%)	0/2313 (0%)
Lung neoplasm [A] *	0/2291 (0%)	1/2313 (0.04%)
Lung neoplasm malignant [A] *	2/2291 (0.09%)	2/2313 (0.09%)
Lung squamous cell carcinoma stage unspecified [A] *	1/2291 (0.04%)	2/2313 (0.09%)
Lymphoma [A] *	0/2291 (0%)	1/2313 (0.04%)
Malignant melanoma [A] *	1/2291 (0.04%)	2/2313 (0.09%)
Malignant pleural effusion [A] *	0/2291 (0%)	1/2313 (0.04%)
Metastases to liver [A] *	0/2291 (0%)	1/2313 (0.04%)
Metastases to lung [A] *	1/2291 (0.04%)	0/2313 (0%)
Metastasis [A] *	1/2291 (0.04%)	0/2313 (0%)
Metastatic carcinoma of the bladder [A] *	1/2291 (0.04%)	0/2313 (0%)
Multiple myeloma [A] *	1/2291 (0.04%)	0/2313 (0%)
Myelodysplastic syndrome [A] *	0/2291 (0%)	1/2313 (0.04%)
Myeloproliferative disorder [A] *	1/2291 (0.04%)	0/2313 (0%)
Nasal cavity cancer [A] *	1/2291 (0.04%)	0/2313 (0%)
Non-small cell lung cancer [A] *	1/2291 (0.04%)	2/2313 (0.09%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Non-small cell lung cancer metastatic [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Ocular neoplasm [A] *	0/2291 (0%)	1/2313 (0.04%)
Oesophageal adenocarcinoma [A] *	2/2291 (0.09%)	1/2313 (0.04%)
Oesophageal cancer metastatic [A] *	1/2291 (0.04%)	0/2313 (0%)
Ovarian adenoma [A] *	0/2291 (0%)	2/2313 (0.09%)
Ovarian cancer [A] *	0/2291 (0%)	1/2313 (0.04%)
Pancreatic carcinoma [A] *	2/2291 (0.09%)	1/2313 (0.04%)
Pancreatic neoplasm [A] *	1/2291 (0.04%)	0/2313 (0%)
Papillary serous endometrial carcinoma [A] *	0/2291 (0%)	1/2313 (0.04%)
Pituitary tumour benign [A] *	0/2291 (0%)	1/2313 (0.04%)
Plasmacytoma [A] *	0/2291 (0%)	1/2313 (0.04%)
Pleura carcinoma [A] *	0/2291 (0%)	1/2313 (0.04%)
Prostate cancer [A] *	6/2291 (0.26%)	11/2313 (0.48%)
Prostate cancer metastatic [A] *	0/2291 (0%)	2/2313 (0.09%)
Prostatic adenoma [A] *	1/2291 (0.04%)	2/2313 (0.09%)
Rectal cancer [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Rectal neoplasm [A] *	1/2291 (0.04%)	0/2313 (0%)
Renal cell carcinoma stage unspecified [A] *	2/2291 (0.09%)	1/2313 (0.04%)
Renal neoplasm [A] *	0/2291 (0%)	1/2313 (0.04%)
Small cell lung cancer metastatic [A] *	0/2291 (0%)	1/2313 (0.04%)
Small cell lung cancer stage unspecified [A] *	0/2291 (0%)	1/2313 (0.04%)
Squamous cell carcinoma [A] *	2/2291 (0.09%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Squamous cell carcinoma of skin [A] *	1/2291 (0.04%)	0/2313 (0%)
Thymoma malignant [A] *	1/2291 (0.04%)	0/2313 (0%)
Tumour ulceration [A] *	0/2291 (0%)	1/2313 (0.04%)
Urethral adenoma [A] *	1/2291 (0.04%)	0/2313 (0%)
Uterine cancer [A] *	2/2291 (0.09%)	0/2313 (0%)
Vulval cancer [A] *	0/2291 (0%)	1/2313 (0.04%)
Nervous system disorders		
Amyotrophic lateral sclerosis [A] *	0/2291 (0%)	1/2313 (0.04%)
Brain mass [A] *	1/2291 (0.04%)	0/2313 (0%)
Carpal tunnel syndrome [A] *	0/2291 (0%)	3/2313 (0.13%)
Cerebrovascular accident [A] *	0/2291 (0%)	2/2313 (0.09%)
Cerebrovascular disorder [A] *	1/2291 (0.04%)	0/2313 (0%)
Convulsion [A] *	0/2291 (0%)	1/2313 (0.04%)
Dementia alzheimer's type [A] *	2/2291 (0.09%)	1/2313 (0.04%)
Diplegia [A] *	0/2291 (0%)	1/2313 (0.04%)
Dizziness [A] *	3/2291 (0.13%)	2/2313 (0.09%)
Epilepsy [A] *	0/2291 (0%)	1/2313 (0.04%)
Facial palsy [A] *	0/2291 (0%)	1/2313 (0.04%)
Guillain-barre syndrome [A] *	0/2291 (0%)	1/2313 (0.04%)
Haemorrhagic stroke [A] *	0/2291 (0%)	1/2313 (0.04%)
Headache [A] *	1/2291 (0.04%)	0/2313 (0%)
Hepatic encephalopathy [A] *	0/2291 (0%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Intracranial aneurysm [A] *	1/2291 (0.04%)	0/2313 (0%)
Ischaemic stroke [A] *	2/2291 (0.09%)	1/2313 (0.04%)
Loss of consciousness [A] *	0/2291 (0%)	1/2313 (0.04%)
Lumbar radiculopathy [A] *	1/2291 (0.04%)	0/2313 (0%)
Metabolic encephalopathy [A] *	0/2291 (0%)	1/2313 (0.04%)
Mononeuritis [A] *	0/2291 (0%)	1/2313 (0.04%)
Partial seizures [A] *	0/2291 (0%)	2/2313 (0.09%)
Pseudobulbar palsy [A] *	1/2291 (0.04%)	0/2313 (0%)
Sciatica [A] *	2/2291 (0.09%)	1/2313 (0.04%)
Spinal claudication [A] *	1/2291 (0.04%)	0/2313 (0%)
Syncope [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Toxic encephalopathy [A] *	0/2291 (0%)	1/2313 (0.04%)
Transient ischaemic attack [A] *	2/2291 (0.09%)	2/2313 (0.09%)
Vascular encephalopathy [A] *	1/2291 (0.04%)	0/2313 (0%)
Vertebrobasilar insufficiency [A] *	1/2291 (0.04%)	0/2313 (0%)
Psychiatric disorders		
Alcohol withdrawal syndrome [A] *	0/2291 (0%)	1/2313 (0.04%)
Alcoholism [A] *	0/2291 (0%)	1/2313 (0.04%)
Anxiety [A] *	0/2291 (0%)	2/2313 (0.09%)
Confusional state [A] *	0/2291 (0%)	1/2313 (0.04%)
Delirium tremens [A] *	0/2291 (0%)	1/2313 (0.04%)
Depression [A] *	3/2291 (0.13%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Generalised anxiety disorder [A] *	1/2291 (0.04%)	0/2313 (0%)
Major depression [A] *	1/2291 (0.04%)	0/2313 (0%)
Mental status changes [A] *	1/2291 (0.04%)	3/2313 (0.13%)
Post-traumatic stress disorder [A] *	0/2291 (0%)	1/2313 (0.04%)
Suicide attempt [A] *	0/2291 (0%)	1/2313 (0.04%)
Renal and urinary disorders		
Bladder obstruction [A] *	0/2291 (0%)	1/2313 (0.04%)
Calculus bladder [A] *	1/2291 (0.04%)	0/2313 (0%)
Calculus urinary [A] *	2/2291 (0.09%)	2/2313 (0.09%)
Cystitis haemorrhagic [A] *	0/2291 (0%)	1/2313 (0.04%)
Cystitis noninfective [A] *	0/2291 (0%)	1/2313 (0.04%)
Diabetic nephropathy [A] *	2/2291 (0.09%)	0/2313 (0%)
Haematuria [A] *	7/2291 (0.31%)	7/2313 (0.3%)
Hydronephrosis [A] *	1/2291 (0.04%)	2/2313 (0.09%)
Nephrolithiasis [A] *	2/2291 (0.09%)	2/2313 (0.09%)
Nocturia [A] *	1/2291 (0.04%)	0/2313 (0%)
Renal colic [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Renal failure [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Renal failure acute [A] *	14/2291 (0.61%)	4/2313 (0.17%)
Renal failure chronic [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Renal impairment [A] *	1/2291 (0.04%)	0/2313 (0%)
Stress urinary incontinence [A] *	0/2291 (0%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Urethral stenosis [A] *	0/2291 (0%)	1/2313 (0.04%)
Urinary bladder polyp [A] *	1/2291 (0.04%)	0/2313 (0%)
Urinary retention [A] *	1/2291 (0.04%)	2/2313 (0.09%)
Reproductive system and breast disorders		
Acquired hydrocele [A] *	1/2291 (0.04%)	0/2313 (0%)
Adnexa uteri cyst [A] *	0/2291 (0%)	1/2313 (0.04%)
Benign prostatic hyperplasia [A] *	8/2291 (0.35%)	10/2313 (0.43%)
Breast discomfort [A] *	1/2291 (0.04%)	0/2313 (0%)
Endometrial hyperplasia [A] *	1/2291 (0.04%)	0/2313 (0%)
Epididymitis [A] *	0/2291 (0%)	1/2313 (0.04%)
Gynaecomastia [A] *	0/2291 (0%)	1/2313 (0.04%)
Penis disorder [A] *	1/2291 (0.04%)	0/2313 (0%)
Prostatitis [A] *	0/2291 (0%)	3/2313 (0.13%)
Uterine polyp [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Uterine prolapse [A] *	1/2291 (0.04%)	0/2313 (0%)
Vaginal prolapse [A] *	0/2291 (0%)	2/2313 (0.09%)
Respiratory, thoracic and mediastinal disorders		
Acute respiratory failure [A] *	1/2291 (0.04%)	0/2313 (0%)
Asthma [A] *	5/2291 (0.22%)	2/2313 (0.09%)
Bronchopneumopathy [A] *	0/2291 (0%)	1/2313 (0.04%)
Chronic obstructive pulmonary disease [A] *	13/2291 (0.57%)	19/2313 (0.82%)
Cough [A] *	0/2291 (0%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Dyspnoea [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Emphysema [A] *	1/2291 (0.04%)	0/2313 (0%)
Epistaxis [A] *	1/2291 (0.04%)	4/2313 (0.17%)
Haemoptysis [A] *	2/2291 (0.09%)	3/2313 (0.13%)
Hypoxia [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Interstitial lung disease [A] *	2/2291 (0.09%)	1/2313 (0.04%)
Lung disorder [A] *	1/2291 (0.04%)	0/2313 (0%)
Nasal polyps [A] *	0/2291 (0%)	1/2313 (0.04%)
Nasal turbinate hypertrophy [A] *	1/2291 (0.04%)	0/2313 (0%)
Obstructive airways disorder [A] *	1/2291 (0.04%)	0/2313 (0%)
Pleural effusion [A] *	3/2291 (0.13%)	4/2313 (0.17%)
Pleurisy [A] *	3/2291 (0.13%)	0/2313 (0%)
Pneumonia aspiration [A] *	0/2291 (0%)	2/2313 (0.09%)
Pneumonitis [A] *	1/2291 (0.04%)	0/2313 (0%)
Pulmonary fibrosis [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Pulmonary mass [A] *	0/2291 (0%)	1/2313 (0.04%)
Pulmonary oedema [A] *	0/2291 (0%)	1/2313 (0.04%)
Respiratory failure [A] *	4/2291 (0.17%)	1/2313 (0.04%)
Sleep apnoea syndrome [A] *	0/2291 (0%)	3/2313 (0.13%)
Skin and subcutaneous tissue disorders		
Decubitus ulcer [A] *	0/2291 (0%)	1/2313 (0.04%)
Dermatitis [A] *	0/2291 (0%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Dermatitis bullous [A] *	0/2291 (0%)	1/2313 (0.04%)
Panniculitis [A] *	1/2291 (0.04%)	0/2313 (0%)
Pemphigoid [A] *	1/2291 (0.04%)	0/2313 (0%)
Photodermatosis [A] *	1/2291 (0.04%)	0/2313 (0%)
Pruritus [A] *	1/2291 (0.04%)	0/2313 (0%)
Psoriasis [A] *	0/2291 (0%)	1/2313 (0.04%)
Rash [A] *	0/2291 (0%)	2/2313 (0.09%)
Skin ulcer [A] *	2/2291 (0.09%)	0/2313 (0%)
Urticaria [A] *	1/2291 (0.04%)	0/2313 (0%)
Social circumstances		
Victim of crime [A] *	1/2291 (0.04%)	0/2313 (0%)
Surgical and medical procedures		
Hip arthroplasty [A] *	0/2291 (0%)	3/2313 (0.13%)
Ileostomy closure [A] *	1/2291 (0.04%)	0/2313 (0%)
Knee operation [A] *	0/2291 (0%)	1/2313 (0.04%)
Pilonidal sinus repair [A] *	0/2291 (0%)	1/2313 (0.04%)
Shoulder arthroplasty [A] *	1/2291 (0.04%)	0/2313 (0%)
Suprapubic catheter insertion [A] *	1/2291 (0.04%)	0/2313 (0%)
Transurethral prostatectomy [A] *	1/2291 (0.04%)	0/2313 (0%)
Vascular disorders		
Angiodysplasia [A] *	0/2291 (0%)	1/2313 (0.04%)
Aortic aneurysm [A] *	1/2291 (0.04%)	1/2313 (0.04%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Femoral arterial stenosis [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Haematoma [A] *	3/2291 (0.13%)	3/2313 (0.13%)
Haemorrhage [A] *	1/2291 (0.04%)	1/2313 (0.04%)
Hypovolaemic shock [A] *	1/2291 (0.04%)	0/2313 (0%)
Iliac artery embolism [A] *	0/2291 (0%)	1/2313 (0.04%)
Lymphoedema [A] *	0/2291 (0%)	1/2313 (0.04%)
Peripheral embolism [A] *	0/2291 (0%)	1/2313 (0.04%)
Thrombophlebitis [A] *	0/2291 (0%)	1/2313 (0.04%)
Varicose vein [A] *	0/2291 (0%)	1/2313 (0.04%)

* Indicates events were collected by non-systematic methods.
A Term from vocabulary, MedDRA (10.1)

Other Adverse Events
Frequency Threshold Above Which Other Adverse Events are Reported: 5%

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Total	1584/2291 (69.14%)	1527/2313 (66.02%)
Cardiac disorders		
Any cardiac disorders [A] *	251/2291 (10.96%)	213/2313 (9.21%)
Gastrointestinal disorders		
Any Gastrointestinal disorders [A] *	573/2291 (25.01%)	478/2313 (20.67%)
Diarrhoea [A] *	222/2291 (9.69%)	142/2313 (6.14%)
Nausea [A] *	122/2291 (5.33%)	71/2313 (3.07%)
General disorders		

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Any general disorders and administration site conditions [A] *	397/2291 (17.33%)	348/2313 (15.05%)
Fatigue [A] *	115/2291 (5.02%)	90/2313 (3.89%)
Oedema peripheral [A] *	147/2291 (6.42%)	119/2313 (5.14%)
Infections and infestations		
Any infections and infestations [A] *	508/2291 (22.17%)	533/2313 (23.04%)
Injury, poisoning and procedural complications		
Any injury, poisoning and procedural complications [A] *	187/2291 (8.16%)	198/2313 (8.56%)
Investigations		
Any investigation disorders [A] *	298/2291 (13.01%)	199/2313 (8.6%)
Metabolism and nutrition disorders		
Any metabolism and nutrition disorders [A] *	171/2291 (7.46%)	183/2313 (7.91%)
Musculoskeletal and connective tissue disorders		
Any musculoskeletal and connective tissue disorders [A] *	364/2291 (15.89%)	376/2313 (16.26%)
Nervous system disorders		
Any nervous system disorders [A] *	362/2291 (15.8%)	365/2313 (15.78%)
Dizziness [A] *	160/2291 (6.98%)	145/2313 (6.27%)
Psychiatric disorders		
Any psychiatric disorders [A] *	106/2291 (4.63%)	125/2313 (5.4%)
Respiratory, thoracic and mediastinal disorders		
Any respiratory, thoracic and mediastinal disorders [A] *	315/2291 (13.75%)	318/2313 (13.75%)
Dyspnoea [A] *	120/2291 (5.24%)	96/2313 (4.15%)

	Dronedarone 400mg Bid	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)
Skin and subcutaneous tissue disorders		
Any skin and subcutaneous tissue disorders [A] *	235/2291 (10.26%)	174/2313 (7.52%)
Vascular disorders		
Any vascular disorders [A] *	179/2291 (7.81%)	187/2313 (8.08%)

* Indicates events were collected by non-systematic methods.
A Term from vocabulary, MedDRA (10.1)

Limitations and Caveats

[Not specified]

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such publication for comment at least 45 days before any submission for publication. If requested by the Sponsor, any submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.

Results Point of Contact:

Name/Official Title: International Clinical Development (ICD), Clinical Study Director
Organization: sanofi-aventis
Phone:
Email: GV-Contact-us@sanofi-aventis.com